Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

Caitlin E. Cox

August 28, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Daily News

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Yael L. Maxwell

February 17, 2022

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Daily News

ASCVD Risk in South Asians Far Exceeds Forecasts by Common Scores

Shelley Wood

July 12, 2021

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

News Daily News

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Michael O'Riordan

January 14, 2021

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

August 2024 Dispatch for the CV Team

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

ASCVD Risk in South Asians Far Exceeds Forecasts by Common Scores

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content